SITC Cancer Immunotherapy Guidelines – Squamous Cell Carcinoma of the Head and Neck (HNSCC) Webinar
Learn more about immunotherapy treatment standards for squamous cell carcinoma of the head and neck (HNSCC) in "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)" publication.
SITC hosted this one-hour webinar on Wednesday, July 24, 2019.
Presenting Faculty:
- Ezra Cohen, MD – University of California San Diego
- Robert L. Ferris, MD, PhD – UPMC Hillman Cancer Center
- Quynh-Thu Le, MD, FACR, FASTRO – Stanford University
- Rom Leidner, MD – Earle A. Chiles Research Institute, Providence Cancer Institute
- Ravindra Uppaluri, MD, PhD – Dana-Farber Cancer Institute
The webinar faculty presented and discussed:
- SITC's cancer immunotherapy guidelines on immunotherapy for the treatment of head and neck cancer
- New FDA approvals and the role of patient biomarker testing in optimizing treatment selection
- Unique case studies that may require adaptation of cancer immunotherapy regimens
- How best to manage immune-related adverse events
Squamous Cell Carcinoma of the Head and Neck (HNSCC) on-demand WEBINAR
SITC Cancer Immunotherapy Guidelines – Non-Small Cell Lung (NSCLC) Cancer Webinar
Learn more about immunotherapy treatment standards for non-small cell lung cancer in "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)" publication.
SITC hosted this one-hour webinar on Thursday, September 13, 2018.
Presenting Faculty:
- Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Patrick Forde, MD – Johns Hopkins University
- Scott N. Gettinger, MD – Yale Cancer Center
- Roy S. Herbst, MD, PhD – Yale Cancer Center
The webinar faculty presented and discussed:
- The role of immunotherapy for the treatment of NSCLC
- The role of patient biomarker testing for prognostic use as well as optimizing treatment selection
- Unique disease cases that may require adaption of immunotherapy utilization
- How best to manage immune-related adverse events
Learn more about immunotherapy treatment standards for melanoma in "An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0" publication.
SITC hosted this one-hour webinar on Monday, July 30, 2018.
Presenting Faculty:
- Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
- John M. Kirkwood, MD – UPMC Hillman Cancer Center
- Ryan J. Sullivan, MD – Massachusetts General Hospital
The webinar faculty presented and discussed:
- The role of immunotherapy for the treatment of melanoma
- The role of patient biomarker testing for prognostic use as well as optimizing treatment selection
- Unique disease cases that may require adaption of immunotherapy utilization
- How best to manage immune-related adverse events
Cutaneous Melanoma on-demand WEBINAR